Related Experiment Videos
In vitro characterization of a recombinant 32P-phosphorylated anti-(carcinoembryonic antigen) single-chain antibody
M R Patrick1, K A Chester, G A Pietersz
1Austin Research Institute, Austin Hospital, Heidelberg, Victoria, Australia.
Abstract:
The major limitations of monoclonal antibody conjugates as therapeutic agents have been their poor tumour targeting, inadequate tumour penetration and immunogenicity. More even and deeper tissue penetration has been demonstrated with smaller antibody fragments. The smaller size and absence of an Fc segment may contribute to a lowered immunogenicity with single-chain antibodies (scFv) and also permit their recombinant engineering and bacterial expression. We describe the successful engineering, expression and pre-clinical characterisation of a phosphorylatable "kemptide" (Leu-Arg-Arg-Ala-Ser-Gly) anti-carcinoembryonic antigen (anti-CEA) scFv (PKS-scFv), for use as a radioimmunotherapeutic agent. Specifically, a yield of 6 mg/l induced culture was obtained. Site-specific phosphorylation was demonstrated without loss of specificity. In vitro assays revealed a selective cytotoxicity of 32P-PKS-scFv for high-CEA-expressing LS-174T cells compared to the low-CEA-expressing HT-29 cells, with a rapid internalisation rate.
Insights
Researchers engineered a novel phosphorylatable single-chain antibody fragment (scFv) targeting carcinoembryonic antigen (CEA). This engineered antibody fragment demonstrated selective cytotoxicity and rapid internalization, offering potential for improved radioimmunotherapy.
Area of Science:
- Biotechnology
- Oncology
- Immunology
Background:
- Monoclonal antibody conjugates face limitations in tumor targeting, penetration, and immunogenicity.
- Smaller antibody fragments, like single-chain variable fragments (scFv), show improved tissue penetration and potentially reduced immunogenicity.
- Recombinant engineering and bacterial expression offer advantages for antibody fragment development.
Purpose of the Study:
- To engineer, express, and pre-clinically characterize a phosphorylatable anti-carcinoembryonic antigen (anti-CEA) scFv (PKS-scFv).
- To evaluate PKS-scFv as a potential radioimmunotherapeutic agent.
- To assess the specificity, phosphorylation, and in vitro cytotoxicity of the engineered scFv.
Main Methods:
- Engineering and bacterial expression of a phosphorylatable anti-CEA scFv (PKS-scFv).
- Site-specific phosphorylation of the engineered scFv.
- In vitro cytotoxicity assays using high-CEA-expressing (LS-174T) and low-CEA-expressing (HT-29) cell lines.
- Assessment of cellular internalization rates.
Main Results:
- Successful engineering and expression of PKS-scFv with a yield of 6 mg/l.
- Demonstration of site-specific phosphorylation without loss of specificity.
- Selective in vitro cytotoxicity of 32P-PKS-scFv against high-CEA-expressing cells.
- Rapid internalization rate observed for the engineered scFv.
Conclusions:
- The engineered PKS-scFv is a promising candidate for radioimmunotherapy due to its specific targeting, phosphorylation capability, and selective cytotoxicity.
- The reduced size and potential for lower immunogenicity of scFv offer advantages over traditional monoclonal antibodies.
- Further pre-clinical evaluation is warranted to explore the therapeutic potential of this novel agent.